Gilead Sciences | 销售和管理费用



Selling And Administration Expenses 更改 日
AbbVie USD 3.29B 562M 2025-03
Agios Pharmaceuticals USD 41.53M 10.17M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amgen USD 1.69B 191M 2025-03
Biogen USD 572.5M 104.8M 2025-03
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.06B 603M 2025-03
Glaxosmithkline GBP 2.7B 632M 2024-12
Incyte USD 325.69M 1.02M 2025-03
J&J USD 5.11B 1.34B 2025-03
Merck USD 2.53B 319M 2025-03
Moderna USD 212M 139M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 161.92M 77.24M 2025-03
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sanofi EUR 2.22B 980M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
United Therapeutics USD 170.1M 7.6M 2025-03
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Gilead Sciences 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - May 2025.